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Objective: This study aimed to estimate the annual health care burden for patients with adrenal
insufficiency [AI; primary (PAI), secondary to pituitary disorder (PIT), and congenital adrenal hy-
perplasia (CAH)] using real-world data.
Methods:Using aUS-based payer database comprising.108millionmembers, strict inclusion criteria
with diagnostic codes and pharmacy records were used to identify 10,383 patients with AI. This included
1014 patients with PAI, 8818 with PIT, and 551 with CAH, followed for .12 months. Patients were
matched 1:1 to controls, based on age (65 years), sex, insurance, and region. Multivariable expenditure
models were estimated for each AI cohort vs controls as well as subsets by glucocorticoid therapy
(hydrocortisone, dexamethasone, prednisone, or multiple therapies). A separate multivariable model
was estimated to assess the association between adherence and expenditures.
Results:Total annual health care expenditure estimates were significantly higher (P, 0.0001) in all AI
cohorts compared with matched controls (PAI $18,624 vs $4320, PIT $32,218 vs $6956, CAH $7677 vs
$4203). Patients with AI have more frequent inpatient hospital stays with up to eight to 10 times more
days in the hospital per year than their matched controls. In each AI cohort, patients onmultiple steroid
therapies had higher expenditures in comparison with patients using hydrocortisone therapy alone. In
PAI and PIT cohorts taking hydrocortisone only, fewer expenditures were found in higher adherence
subsets.
Conclusion:PatientswithAI demonstrate a substantial annual health care burden. Expenditures vary
by underlying cause and treatment and are reduced in patients with higher adherence to glucocorticoid
replacement.
Copyright © 2017 Endocrine Society
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Adrenal insufficiency (AI) is a rare, life-threatening endocrine disease characterized by in-
sufficient production of corticosteroid hormones [1]. AI can be classified as primary or sec-
ondary. Primary AI (PAI), is a condition affecting the adrenal glands, associated with loss of
both glucocorticoid and mineralocorticoid hormones. Congenital adrenal hyperplasia (CAH),
an inherited form of PAI, affects one in 10,000 to one in 20,000 newborns per year [2]. Hy-
popituitarism, or secondary AI, arises due to a hypothalamic or pituitary disorder (PIT) with
Abbreviations: AI, adrenal insufficiency; CAH, congenital adrenal hyperplasia; PAI, primary adrenal insufficiency; PIT, pituitary
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glucocorticoid deficiency alone when the renin–angiotensin–aldosterone axis remains intact
[3]. Conventional treatment of both PAI and secondary AI involves a lifelong regimen of
steroid replacement therapy, with once-, twice-, or thrice-daily dosing with a glucocorticoid
[4]. The most commonly prescribed glucocorticoid for this regimen is hydrocortisone, with
alternatives being prednisone, prednisolone, and dexamethasone [3].
The literature on cost of treatment of AI is very limited. A recent study involving about
20,000 patients in the United Kingdom estimated the cost per patient of £1922 (USD $3,411)
giving a total annual cost for the AI patient population of the UK of £39.7 million (USD $70.5
million) [5]. There are several cost drivers of AI that include but are not limited to diagnosis,
less efficacious treatment strategies, comorbidities associated with the underlying disease,
and possible side effects induced by the glucocorticoid replacement. The symptoms of AI are
relatively nonspecific, often leading to delayed diagnosis, which may result in hospital ad-
missionwith an acute life-threatening adrenal crisis [1]. The chronic nature of AI significantly
increases cost because it requires lifelong replacement therapy and physician office visits.
During glucocorticoid therapy, adherence may be made even more difficult by problems
related to adrenal crisis and hospitalization, as well as patient concerns about the use of
glucocorticoid therapy [6–8]. These long-term effects include decreased quality of life, reduced
productivity (absenteeism), premature mortality, and long-termmorbidity including obesity,
osteoporosis, impaired glucose tolerance, cardiovascular disease, and infection [3].
A recent analysis, using the same source dataset, showed that AI patients have significant
comorbidities, including increased risk of diabetes mellitus, hypertension, hyperlipidemia,
depression, and anxiety, in comparison with matched controls [9]. In addition to increased
comorbidity burden, PAI and PIT patients experienced significantly higher rate of hospital
admissions than the matched controls, largely due to infection. The purpose of this study is to
build upon those clinical findings of increased inpatient hospitalizations and morbidity
utilizing a large national payer database in the United States to estimate the annual health
care burden for patients with AI.
1. Methods
A. Data Source
This study used the same database and patient acquisition as our recent study on comor-
bidities of patients with AI [9], which used administrative health claims data from Truven
Health MarketScan® Commercial and Medicare databases from January 2006 to June 2011,
including a total of 108,271,287 patients. MarketScan contains individual-level, deidentified
health care claims information from employers, health plans, hospitals, and Medicare pro-
grams in the United States and is fully compliant with the Health Insurance Portability and
Accountability Act of 1996 [10].
B. Cohort Definitions and Selection Criteria
Patients were classified into three cohorts (PAI, PIT, or CAH) based on the algorithm from
Stewart et al. [9], which applies strict inclusion criteria with diagnostic codes and pharmacy
records of steroid prescriptions. To exclude patients whomay have been prescribed high doses
of steroids for conditions other than AI, in all cohorts, patients were excluded if there was
documentation of glucocorticoid and/or mineralocorticoid usage with a pharmacy fill within
the last 30 days of .10 mg/d of prednisolone/prednisone, .1 mg/d of dexamethasone,
or .50 mg/d of hydrocortisone.
Following selection of subjects with the inclusion/exclusion criteria from Stewart et al.
[9], each AI patient cohort was further classified into monotherapy (hydrocortisone only,
dexamethasone only, or prednisolone/prednisone only) or multiple therapies based on the
pharmacy fills in the 6 to 12 months after the first diagnosis time window. A lag of 6 months
from the date of diagnosis was important for the adherence calculation to ensure the stability
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of a patients’medication regimen. Furthermore, because glucocorticoid adherence can only be
estimated based on pharmacy fill claims, patients with adherence of $50% were identified,
and sample size permitting, analyzed separately. This subanalysis used$50% adherence as a
threshold to ensure that cohort definitions were robust to varying degrees of drug adherence.
By setting this threshold, some appropriate patients might be omitted, but this analysis
intentionally errs on the side of caution in order not to reach inaccurate conclusions about AI
and replacement therapy.
AI patients across the three cohorts utilizing hydrocortisone onlywith threshold adherence
rates of $50% (hereby known as the hydro-only subset) were analyzed as a subset to ensure
the robustness of the cohorts. Finally, to explore the relationship between adherence and
expenditures, the hydro-only subset was further divided by taking the initial threshold
adherence criterion of$50%and creating the following two categories: patientswhowere 50%
to 75% adherent vs patients who were .75% adherent.
C. Statistical Analysis
Every patient meeting inclusion and exclusion criteria within each AI cohort (PAI, PIT, and
CAH) was matched one-to-one to a control group in the same insurance database (matched
control). The matched control patients are not necessarily “healthy” controls, as they are in a
database related to receiving health care, but rather, patientswhosemedical condition(s) does
not include AI. Patients were matched using the greedy algorithm based on age (within
5 years), sex, insurance type (commercial or Medicare), and region (Northeast, Northcentral,
South, West, or unknown) [11, 12].
All study measures were summarized using descriptive statistics. Patient demographics
and expenditureswere summarized in separate data tables and figures. Continuous variables
were presented as the mean and standard deviation. Categorical variables were summarized
with the count and percentage in each category. Health care expenditures included all in-
patient and outpatient (emergency room, office visits, laboratory, radiology, and other pro-
cedures) expenditures in the first year after index diagnosis. Average inpatient admissions,
average total hospital days, and average outpatient visits were reported for each AI cohort, as
well as the PAI and PIT hydro-only subsets and the PIT 50% adherence subset.
To estimate the incremental annual health care expenditures for each AI cohort overall
(PAI, PIT, and CAH) and their two subsets (adherence of $50% and hydro-only) compared
with theirmatched control, multivariable generalized linearmodelswere estimated using the
gamma log-link function. The log-gamma model was chosen due to the nature of the outcome
variable, health care expenditures, which is often right skewed. Thismodel takes into account
the distribution of the outcome variable without the need for complex retransformation
procedures (e.g., natural logarithmic transformation). Expenditures (2006 to 2011) were
converted to 2015 dollars using the Consumer Price Index from the Bureau of Labor Statistics
[13]. Model adjustments after matching included year of diagnosis, and important patient
demographics including age, sex, insurance plan, and plan type. Multivariable expenditure
models were also estimated within each AI cohort by drug treatment (hydrocortisone,
dexamethasone, prednisone, or multiple therapies) and, data permitting, their two subsets
with the reference group for pairwise comparisons being the hydrocortisone only group.
Additional multivariable expenditure models were estimated for the hydro-only cohort by
the two categories of their hydrocortisone adherence (50% to 75% vs.75%). Due to the small
sample size of CAHpatients taking only hydrocortisone, this analysiswas only possible for the
PAI and PIT cohorts.
2. Results
A total of 10,383 AI patients were identified from MarketScan commercial and Medicare
databases for inclusion in the PAI (n = 1014), PIT (n = 8818), and CAH (n = 551) cohorts. Full
patient attrition is shown in Fig. 1. Baseline demographics were similar between AI and
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matched control patients as designed (Table 1).Mean age (6standard deviation)was lowest in
theCAHgroup (32.06 18.3 years) comparedwithPAI (50.86 17.2 years) andPIT (48.06 16.0
years), with almost 30% of CAH patients under 18 years of age. Female sex predominated in
all AI cohorts (PAI, 64.4%; PIT, 59.3%; and CAH, 67.9%). The majority of patients had
commercial insurance coverage (PAI, 81.0%; PIT, 87.7%; and CAH, 97.3%).
Total annual health care expenditure estimates were significantly higher (P , 0.0001) in
all AI cohorts compared with their matched controls (PAI, $18,624 vs $4320; PIT, $32,218 vs
$6956; CAH, $7677 vs $4203; Table 2). Health care expenditure estimates were highest in the
PIT cohort with an incremental annual health care burden of $25,262, followed by PAI
$14,304 and CAH $3474. For the PIT cohort, when examining the subset of patients with at
least 50% adherence, their annual estimated costs were confirmatory (PIT, $32,218, vs PIT at
least 50% adherence, $32,456). When analyzing patients with both adherence $50% and
hydrocortisone recorded as the only glucocorticoid replacement (hydro-only subset), their
estimated annual health expenditureswere lower than the full sample (Table 2; PAI, $18,624,
vs PAI hydro-only, $10,714; PIT, $32,218, vs PIT hydro-only, $26,251).
Figure 1. Attrition diagram. aICD-9 diagnosis (Dx) codes: 227.3–Benign neoplasm of
pituitary gland and craniopharyngeal duct, 237.0–Neoplasm of uncertain behavior
of pituitary gland and craniopharyngeal duct, 239.7–Neoplasm of unspecified nature of
endocrine glands and other parts of nervous system, 253.2–Panhypopituitarism, 253.4–Other
anterior pituitary disorders, 253.7–Iatrogenic pituitary disorders, 253.8–Other disorders of the
pituitary and other syndromes of diencephalohypophyseal origin, 253.9–Unspecified disorder of the
pituitary gland and its hypothalamic control, 255.2–Adrenogenital disorders, 255.4–Corticoadrenal
insufficiency, 255.41–Glucocorticoid deficiency. bFinal AI samples matched to a cohort by age, sex,
insurance type, and region. Only the PIT 50% adherence subset is displayed due to available sample
size for each cohort. Adapted with permission from [9].
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Substantial differenceswere found in total annual health care expenditure estimates for AI
patients in comparison with matched controls (Table 2). The substantial increase in ex-
penditures for the AI cohorts are on the basis of a mix of both inpatient and outpatient health
care utilization.When examining this incremental burden for each AI cohort, the distribution
of health care utilization by inpatient vs outpatient is evenly split with the exception of the
CAH cohort (PAI: inpatient, 59%, vs outpatient, 41%; PIT: inpatient, 54%, vs outpatient, 46%;
CAH: inpatient, 3%, vs outpatient, 97%). To understand these differences in greater detail,
summary statistics of health care utilization measures including inpatient admissions, av-
erage total days spent in the hospital, and average outpatient visits were compared (Fig. 2).
PAI patients had average annual number of inpatient admissions of 0.68 compared with 0.12
in the matched control; the PAI hydro-only subset had a similar difference (PAI hydro-only,
0.56 vs 0.10). ThePIT cohort had an average of 0.54 admissions vs 0.11 for thematched control
and this was similar for the hydro-only subset and $50% adherent cohort (0.63 vs 0.13).
Among the CAH cohort, the CAH patients had 0.14 inpatient admissions compared with the
0.08 average annual admissions amongmatched controls. The average total hospitalized days
were highest in the PAI cohort with 4.2 days in comparison with 0.4 among controls. AI
patients were hospitalizedmore frequently and spent up to eight to 10 timesmore days in the
hospital than their matched controls. Furthermore AI patients had approximately twice as
many outpatient visits per year compared with matched controls (Fig. 2). Outpatient visits
Table 1. Patient Demographics at Baseline
PAI PIT CAH
Matched pairs N = 1014 N = 8818 N = 551
Age, y
Mean 50.8 48.0 31.9
Standard deviation 17.2 16.0 18.3
Sex, %
Male 35.6 40.8 32.1
Female 64.4 59.3 67.9
Insurance coverage, %
Commercial 81.0 87.7 97.3
Medicare 19.0 12.3 2.7
Region, %
Northeast 12.3 14.6 15.4
Northcentral 31.0 25.7 22.5
South 33.8 43.3 43.6
West 22.4 15.3 17.6
Unknown 0.5 1.0 0.9
Adapted with permission from [9].
Table 2. Total Annual Expenditures by AI Cohort and Matched Controls
Pairs, n Cohort Case Estimate Control Estimate
1014 PAI $18,624 $4320
489 PAI hydro-onlya $10,714 $2901
8818 PIT $32,218 $6956
983 PIT hydro-only $26,251 $6566
1529 PIT 50% onlyb $32,456 $6846
551 CAH $7677 $4203
aHydro-only refers to patients in the PAI and PIT cohorts with hydrocortisone use only and a threshold of $50%
adherence.
bPIT 50% only refers to the subset of the PIT cohort with $50% adherence. Only PIT 50% adherence subset is
displayed due to available sample size for each cohort.
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included those to the emergency department, laboratory, radiology unit, physician office, and
other services. PAI patients had an average of 38.6 total outpatient visits compared with 17.8
among controls. The PIT cohort had an average of 41.1 visits with less in the hydro-only cohort
(33.3 visits).
Annual health care expenditures for the AI cohorts were compared with each other based
on their record of glucocorticoid replacement therapy. The annual health care expenditures by
Figure 2. Average health care utilization (inpatient, hospital days, outpatient) by AI cohort.
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four types of glucocorticoid replacement therapy were estimated for each of the three AI
cohorts: (1) hydrocortisone, (2) dexamethasone, (3) prednisone, and (4)multiple therapies. For
the PIT cohort, Table 3 also reports findings for the subset of patients with threshold ad-
herence of at least 50%. Across all three cohorts, estimated annual health care expenditures
for patients on dexamethasone therapy compared with those taking hydrocortisone were not
statistically significantly different. However, the PAI dexamethasone group was very small
with only 15 patients. Patients on prednisone therapy had significantly higher total ex-
penditures in the PAI and CAH cohorts (PAI, P = 0.009; CAH, P = 0.0134) and significantly
lower total expenditures in the PIT cohort (P # 0.0001) in comparison with patients in the
same cohort on hydrocortisone. However, in the PIT subset of patients with$50% adherence,
these findings were no longer statistically significant. In all AI cohorts including the
PIT$50%adherence cohort, patientswho usedmultiple glucocorticoid replacement regimens
had higher total annual expenditures compared with patients who received hydrocortisone
alone (PAI, P# 0.0001; PIT, P# 0.0001; PIT 50%, P# 0.0001; and CAH, P = 0.0350; Table 3).
When examining the two levels of adherence by expenditures for the hydro-only subset of
patients with PAI and PIT, both cohorts showed a decrease in expenditures as adherence
increased (Fig. 3).
3. Discussion
This study examined the real-world health care expenditures associated with AI and further
investigated expenditures based on types of glucocorticoid replacement therapy and pre-
sumed medication adherence. Substantial health care expenditures occurred in each AI
cohort, ranging from two to four times higher thanmatched controls. Health care expenditure
estimates were highest in the PIT cohort ($32,218 vs $6956) followed by PAI ($18,624 vs
$4320) and CAH cohorts ($7677 vs $4203). These findings are similar to the results of a study
of diabetes treatment cohorts in the same claims database. Bonafede et al. [14] found that all
cause medical expenditures for the first year after type 2 diabetes diagnosis ranged from
Figure 2. (Continued)
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$8591 to $20,350, based on severity cohort. Increased health care utilization across the three
cohorts was explained by amix of both inpatient and outpatient visits. This increased burden
was confirmed even in the cohort with $50% adherence.
Annual health care expenditures were estimated for the following four categories of
glucocorticoid replacement therapy in each cohort: (1) hydrocortisone, (2) dexamethasone, (3)
prednisone, and (4) multiple therapies. Across cohorts, the expenditures associated with
dexamethasone were not statistically higher than the expenditures associated with hydro-
cortisone treatment. Significantly higher annual expenditures were estimated for patients on
prednisone therapy in both the PAI and CAH cohorts. In the PIT cohort, patients taking
prednisone had significantly lower annual expenditures in comparison with PIT patients on
hydrocortisone.
In each AI cohort, patients with multiple glucocorticoid replacement therapies had
the highest expenditures. This finding highlights the difficulty in treating AI and how
challenging it can be to find themost effective therapy for each patient [15]. Titrationmust
be based on clinical judgment due to the lack of an ideal biochemical test. The choice of
therapy may be due to attempts to control symptoms and signs related to AI which may
reflect the use of multiple therapies in older sicker patients who have higher health care
costs.
In the PAI and PIT hydro-only cohorts, higher adherence resulted in lower expendi-
tures. This may be due to patients being less likely to experience adrenal crisis if they are
more adherent to glucocorticoid replacement therapy. A case series of three AI patients
found that with high adherence due to continuous subcutaneous hydrocortisone infusion,
patients reported symptom improvement and two of the three cases had reduced hospital
admission rates. The decrease in hospital admissions and resulting reduction in inpatient
length of stay, reduced treatment costs in comparison with the year prior to continuous
infusion [16]. Adherence is commonly linked to reduced cost of treatment, and alterna-
tively, poor adherence has been cited by the World Health Organization as a driver of
health care cost worldwide [17]. The World Health Organization report addressed the
effect of adherence in chronic illnesses including hypertension, asthma, and diabetes. In
the case of diabetes, the direct and indirect costs of complications attributed to poor control
of diabetes were three to four times higher than the cost of complications in patients in
good control. A survey on medication adherence and patient experience reported on
Table 3. Total Annual Expenditures by AI Drug Cohort
AI Cohort Drug Cohort
Cohorts 50% Adherencea
N Expenditures P Valueb N Expenditures P Valueb
PAI
Hydrocortisone 631 $17,358 —
Dexamethasone 15 $9431 0.0847
Prednisone 166 $23,701 0.009
Multiple therapies 202 $27,045 ,0.0001
PIT
Hydrocortisone 1802 $37,281 — 983 $24,479 —
Dexamethasone 1077 $40,749 0.0511 27 $27,424 0.6679
Prednisone 4881 $21,955 ,0.0001 163 $23,376 0.6939
Multiple therapies 1058 $55,862 ,0.0001 356 $46,336 ,0.0001
CAH
Hydrocortisone 147 $5048 —
Dexamethasone 148 $5210 0.8296
Prednisone 187 $7132 0.0134
Multiple therapies 69 $7354 0.0350
aOnly PIT 50% adherence subset is displayed due to available sample size for each cohort.
bP values compare total expenditures of drug cohort vs hydrocortisone (hydrocortisone is the reference group for
pairwise comparisons).
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adherence to glucocorticoid therapy. Only 15% of surveyed AI patients reported being fully
adherent to the doses and timing of doses [8].
It is notable that the CAH cohort had the lowest cost as compared with the other cohorts.
This may be due to the lower mean age of the CAH cohort; nearly 30% were under the age of
18. Annual expenditures in the PIT group were higher than in the PAI and CAH groups. This
finding may be due to several factors, including care for the underlying condition which
includesmultiple hormonal deficiencies. For example, PIT patients selected into this analysis
are likely to have panhypopituitarism as well as diabetes insipidus. Therefore, along with
their glucocorticoid therapy they would also need desmopressin, sex steroid, and thyroxine
replacement as well as the potential for recombinant human growth hormone. Although this
analysis did not investigate magnetic resonance imaging (MRI) use specifically, PIT patients
have regular head MRIs to monitor their pituitary-area tumor and typically have other
pituitary hormone deficiencies also requiring treatment.
The UK cost of illness study suggested that inpatient admissions are a major cost driver of
AI [5]. In a recent analysis, using the same cohorts as the current study, we found hospital
inpatient admissions to be significantly higher in AI patients vs controls: for one admission in
the matched control group, there were 4.64 admissions in the PAI cohort P , 0.0001. This
finding was similar in the PIT cohort with four inpatient admissions to every one in the
matched controls (P, 0.0001) [9]. These higher inpatient admissions are consistent with the
high expenditures found in this analysis.
A. Data Limitations
Wemost likely did not capture all AI patients in the database. For the purpose of this analysis,
we were striving to avoid including patients where we lacked a high level of certainty that
the diagnosis was correct, particularly to ensure we excluded those who might have been
treated with therapeutic (vs replacement) glucocorticoids for other conditions that are known
to be associated with increased morbidity. We recognize that this strategy omitted some
Figure 3. Expenditures by adherence subsets.
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appropriate patients, but preferred to err on the side of caution in order not to reach in-
accurate conclusions about AI and its replacement.
The limitations of administrative claims-based data—including lack of generalizability to
noninsured populations, clinical outcomes being imputed from data not prepared for research
purposes, and the underreporting of certain events and diagnoses—are well known. Ad-
ministrative claims data are collected for the purpose of billing and reimbursement, not for
coordinating medical care or conducting outcomes research. The data are subject to coding
errors and underreporting of clinical conditions which do not trigger a billable event. Lab-
oratory results, death outside the hospital setting, and physician notes are absent so specific
medical details cannot be determined. Although prescription fills are available, such data do
not reveal when or if the patient actually took the prescribed medication; likewise, physician
instructions for taking medication are not available in the database and must be imputed
using package size, pill dose strength, and number of pills dispensed. Furthermore, in this
database, the drug claims are not linked to diagnoses, which mean that for this analysis,
multiple steroid therapies may relate to the fact that the patient has other comorbidities that
require other steroid treatments. Finally, limitations common to all retrospective research
apply: most importantly, the lack of random allocation to treatment and the absence of
protocols for follow up of all treatment cohorts, starting at a similar point in their disease
course.
Despite these shortcomings, administrative data have been widely used to evaluate the
association between treatments and clinical outcomes, particularly when a portrayal of
patient experience outside the controlled setting of the clinical trial is useful, such as in the
rare disorder AI.
4. Conclusion
This analysis of claims data includedmore than 10,000 AI patients divided into PAI, PIT, and
CAH cohorts. Substantial annual health care expenditures were found for each of the AI
cohorts in comparison with matched controls, with the PIT cohort having the highest annual
expenditures. Patientswith AI havemore frequent inpatient hospital stayswith up to eight to
10 times more days in the hospital per year than their matched controls. When comparing AI
patients within each cohort based on their drug regimen, patients receiving prednisone
therapy vs hydrocortisone therapy had significantly higher total annual expenditures in the
PAI and CAH and significantly lower total expenditures in the PIT cohort. Patients taking
only hydrocortisone and meeting the threshold of$50% adherence were found to have lower
expenditures when medication adherence was 75% or higher. Future research is needed to
further understand the increase in health care utilization (surgery, radiotherapy, MRI, etc.)
Appendix. ICD-9 Codes Used to Define Cohorts
ICD-9 Diagnosis Code ICD-9 Diagnosis Description Cohort
255.4 Corticoadrenal insufficiency PAI
255.41 Glucocorticoid deficiency PAI
227.3 Neoplasm, benign, pituitary gland PIT
237.0 Neoplasm, uncertain behavior, pituitary gland PIT
239.7 Neoplasm, unspecified nature, endocrine glands PIT
253.2 Panhypopituitarism PIT
253.4 Other anterior pituitary disorders PIT
253.7 Disorder, iatrogenic pituitary PIT
253.8 Other disorders of the pituitary and other syndromes
of diencephalohypophyseal origin
PIT
253.9 Unspecified disorders of the pituitary gland and its
hypothalamic control
PIT
255.2 Adrenogenital disorders CAH
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that was observed in AI pituitary patients. In conclusion, compared with matched controls,
patients with AI, irrespective of cause, demonstrate a substantial annual health care burden.
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